NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

CompletedPhase 4

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Conditions: Multiple Sclerosis

Interventions: Mavenclad®

Countries: Australia, Austria, Canada, Czechia, Finland, France, Germany, Hungary

The primary purpose of this study was to evaluate the long-term effectiveness of Mavenclad® tablets, in terms of disease activity and safety, in participants with highly-active relapsing multiple sclerosis (RMS) previously participating in the MAGNIFY MS trial MS700568\_0022 (NCT03364036).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Participants of the MAGNIFY Multiple Sclerosis (MS) trial who received at least a single dose of cladribine tablets during the MAGNIFY MS trial and data on Magnetic resonance imaging (MRI) is available/acquired from at least parent study Month 18 or Month 24 visit and Expanded Disability Status Scale (EDSS) and relapse from parent study Month 24 visit
* Capable of giving signed informed consent

Exclusion Criteria:

* Participant is considered by the Investigator, for any reason, to be an unsuitable candidate for the study
* Participation in other studies/trials

Locations (46)

Liverpool, Australia
New Lambton, Australia
Klagenfurt, Austria
Salzburg, Austria
Edmonton, Canada
London, Canada
Montreal, Canada
Vancouver, Canada
Brno, Czechia
Brno, Czechia
Hradec Králové, Czechia
Pardubice, Czechia
Prague, Czechia
Tampere, Finland
Turku, Finland
Montpellier, France
Nice, France
Nîmes, France
Poissy, France
Rennes, France
Strasbourg, France
Dresden, Germany
Essen, Germany
Hamburg, Germany
Hanover, Germany
Leipzig, Germany
Szeged, Hungary
Ashkelon, Israel
Haifa, Israel
Tel Litwinsky, Israel
+ 16 more on CT.gov